Matthews J, Adomat H, Farrell N, King P, Koch C, Lord E, Palcic B, Poulin N, Sangulin J, Skov K
Department of Medical Biophysics, BC Cancer Research Centre, Vancouver, Canada.
Br J Cancer Suppl. 1996 Jul;27:S200-3.
The monoclonal antibody ELK3-51 was previously developed to detect adducts of the 2-nitroimidazole EF5. Direct immunofluorescence was used to detect adducts of EF5 or of a platinated derivative cis-[PtCl2(NH3)EF5] in SCCVII cells treated under aerobic or hypoxic conditions. Fluorescence measurements of these cells using both image and flow cytometric methods were compared, giving similar profiles. Platination significantly decreased immunofluorescence levels (approximately 4-fold less than EF5) after 3 h in hypoxia, but also increased levels after exposure in air (approximately 1.5 x) such that the hypoxic ratio decreased from approximately 50 to approximately 13. Platinated EF5 also showed significantly greater cytotoxicity than its parent in both aerobic and hypoxic cells. These results are consistent with targeting of EF5 to DNA, which was confirmed qualitatively by confocal microscopy.
单克隆抗体ELK3-51先前已被开发用于检测2-硝基咪唑EF5的加合物。在有氧或缺氧条件下处理的SCCVII细胞中，使用直接免疫荧光法检测EF5或铂化衍生物顺式-[PtCl2(NH3)EF5]的加合物。使用图像和流式细胞术方法对这些细胞进行荧光测量，并进行比较，得到了相似的结果。在缺氧条件下3小时后，铂化显著降低了免疫荧光水平（比EF5低约4倍），但在空气中暴露后也增加了水平（约1.5倍），使得缺氧比率从约50降至约13。铂化的EF5在有氧和缺氧细胞中也显示出比其母体更大的细胞毒性。这些结果与EF5靶向DNA一致，共聚焦显微镜定性证实了这一点。
